BioDelivery Sciences Announces Hiring of George Ng as General Counsel

    BioDelivery Sciences Announces Hiring of George Ng as General Counsel

PR Newswire

RALEIGH, N.C., Dec. 17, 2012

RALEIGH, N.C., Dec. 17, 2012 /PRNewswire/ --BioDelivery Sciences
International, Inc. (Nasdaq: BDSI) announced today the hiring of George K. Ng
as Senior Vice President & General Counsel. In this capacity, Mr. Ng will be
responsible for overseeing BDSI's legal, compliance and intellectual property
activities. Mr. Ng will report directly to Dr. Mark A. Sirgo, President and
Chief Executive Officer.

(Logo: )

Mr. Ng has more than a decade of experience in both law and the pharmaceutical
and life sciences fields. Mr. Ng has held various senior management positions
with publicly-traded, global biotechnology and pharmaceutical companies,
including Spectrum Pharmaceuticals, Inc. and Alpharma, Inc., with oversight
over legal, intellectual property, litigation and compliance matters.
Additionally, Mr. Ng has been responsible for the legal lead in due diligence,
negotiations and contract preparation for multiple business development
transactions, including U.S. and ex-U.S. licenses, global collaboration
agreements and intellectual property and product acquisitions.

Most recently in private practice, Mr. Ng was a partner in two AMLAW 200 law
firms where he had leadership roles, including establishing the life sciences
practice group for one firm and heading it as the national co-chair. In his
private practice positions, Mr. Ng's responsibilities included patent and
trademark prosecution, licensing and litigation support, with areas of
expertise including drug delivery technologies and medical devices.

In 2012, Mr. Ng was a recipient ofM&A Advisor's Top 40 Under 40 Award. In
addition, in 2010, MDB Capital recognized Mr. Ng (and the company where he led
intellectual property efforts) for its Best and Brightest Award and as an
Astrum Award nominee for a pharmaceutical patent portfolio that he developed
and managed.

Mr. Ng earned a Juris Doctor (J.D.) degree in law from the University of Notre
Dame School of Law and a Bachelor of Arts and Sciences (B.A.S.) dual degree in
Biochemistry & Economics from the University of California, Davis.

About BioDelivery Sciences International

BioDelivery Sciences International (NASDAQ: BDSI) is a specialty
pharmaceutical company that is leveraging its novel and proprietary patented
drug delivery technologies to develop and commercialize, either on its own or
in partnerships with third parties, new applications of proven therapeutics.
BDSI is focusing on developing products to meet unmet patient needs in the
areas of pain management and addiction. BDSI's pain franchise currently
consists of two products utilizing the patented BEMA technology. ONSOLIS
(fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U.
(where it is marketed as BREAKYL), for the management of breakthrough pain in
opioid tolerant, adult patients with cancer. The commercial rights are
licensed to Meda for all territories worldwide except for Taiwan (licensed to
TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.). BDSI's
second pain product, BEMA Buprenorphine, is being developed for the treatment
of moderate to severe chronic pain and is licensed on a worldwide basis to
Endo Health Solutions. Additionally, BDSI is developing a high dose
formulation of buprenorphine in combination with naloxone (BNX) for the
treatment of opioid dependence. Both BEMA Buprenorphine and BNX are in Phase
3 clinical development. BDSI's headquarters is located in Raleigh, North
Carolina. For more information visit

Cautionary Note on Forward-Looking Statements

This press release and any statements of representatives and partners of
BioDelivery Sciences International, Inc. (the "Company") related thereto
contain, or may contain, among other things, certain "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve significant risks and
uncertainties. Such statements may include, without limitation, statements
with respect to the Company's plans, objectives, projections, expectations and
intentions and other statements identified by words such as "projects," "may,"
"will," "could," "would," "should," "believes," "expects," "anticipates,"
"estimates," "intends," "plans," "potential" or similar expressions. These
statements are based upon the current beliefs and expectations of the
Company's management and are subject to significant risks and uncertainties,
including those detailed in the Company's filings with the Securities and
Exchange Commission and those that relate to the Company's ability to leverage
the expertise of employees and partners to assist the Company in the execution
of its strategy. Actual results may differ significantly from those set forth
in the forward-looking statements. These forward-looking statements involve
certain risks and uncertainties that are subject to change based on various
factors (many of which are beyond the Company's control). The Company
undertakes no obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise, except as
required by applicable law.

BDSI^®and BEMA^®are registered trademarks of BioDelivery Sciences
International, Inc. The BioDelivery Sciences logo is a trademark owned by
BioDelivery Sciences International, Inc. ONSOLIS^®is a registered trademark
of Meda Pharmaceuticals, Inc. BREAKYL™ is a trademark owned by Meda Pharma
GmbH & Co. KG.

© BioDelivery Sciences International, Inc. All rights reserved.

SOURCE BioDelivery Sciences International, Inc.

Contact: Brian Korb, Senior Vice President, The Trout Group LLC,
+1-646-378-2923,; Al Medwar, Vice President, Marketing
and Corporate Development, BioDelivery Sciences International, Inc.,
Press spacebar to pause and continue. Press esc to stop.